AZNAstraZenecaRunning, no new patients
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Breast Cancer; HER2-positive; Metastatic
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,157 (final count)
- Started
- Apr 26, 2021
- Main results expected
- May 3, 2027
- Fully finished
- Dec 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment
Measured over: Until progression or death, assessed up to approximately 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04784715 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC